Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
24 hedge funds and large institutions have $6.37M invested in Turnstone Biologics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 24 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.44% less ownership
Funds ownership: 54.92% → 49.47% (-5.4%)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
49% less funds holding
Funds holding: 47 → 24 (-23)
81% less capital invested
Capital invested by funds: $33.3M → $6.37M (-$26.9M)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$93.4K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$57.9K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$56K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$14K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.2M |
| 2 |
ZP
Zimmer Partners
New York
|
-$566K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$286K |
| 4 |
Goldman Sachs
New York
|
-$192K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$134K |
TSBX Hedge Fund Activity: Q3 2024 in Review
24 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q3 2024, worth a combined $6.37M — down 81% from $33.3M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TSBX and 1 opened new positions — a net loss of 23 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Geode Capital Management, adding an estimated $93.4K. The largest seller was Eventide Asset Management, exiting entirely with an estimated $1.2M sold.
- 24 institutional investors held Turnstone Biologics (TSBX) as of Q3 2024, down from 47 in Q2 2024.
- Funds reported $6.37M of Turnstone Biologics stock for Q3 2024, down 81% quarter-over-quarter.
- 1 fund opened new Turnstone Biologics positions in Q3 2024 and 24 closed out, a net change of -23 holders.
- The largest Turnstone Biologics buyer in Q3 2024 was Geode Capital Management, an estimated $93.4K added.
- The largest Turnstone Biologics seller in Q3 2024 was Eventide Asset Management, an estimated $1.2M sold.
Based on aggregated 13F filings for Q3 2024.